Knight Therapeutics Inc. reports initial insider ownership in 60 Degrees Pharmaceuticals, Inc. (SXTP) as a ten percent owner. It holds 658,629 shares of common stock, $0.0001 par value per share, directly as of July 22, 2026, with no buy or sell transaction specified.
Knight Therapeutics Inc. filed a Schedule 13G reporting a passive ownership stake in 60 Degrees Pharmaceuticals, Inc. common stock. As of July 22, 2026, Knight beneficially owns 658,629 shares of common stock, representing 19.85% of the class. This percentage is based on 2,659,288 shares outstanding as of May 15, 2026. Knight has sole voting power and sole dispositive power over all 658,629 shares, with no shared voting or dispositive power reported.
60 Degrees Pharmaceuticals, Inc. furnished an updated investor presentation describing its strategy to develop and commercialize products for vector-borne diseases. The company’s lead product is ARAKODA (tafenoquine), an FDA-approved malaria prophylaxis since 2018 targeting a stated $50–70M U.S. malaria prevention market.
The presentation outlines plans to expand tafenoquine into babesiosis, including FDA orphan-drug status granted in 2024 and multiple clinical programs: a randomized hospital study in acute babesiosis with an interim analysis planned after at least 24 patients by late 2026, an expanded-access study in relapsing immunosuppressed patients, and a Phase II open-label study in chronic babesiosis.
Management highlights intellectual property with four Orange Book-listed U.S. patents for tafenoquine expiring in December 2035, recent equity financing (a $5M public offering and about $4M raised via an at-the-market program), and 2.66 million common shares outstanding as of March 31, 2026. The risk discussion includes substantial doubt about the company’s ability to continue as a going concern, dependence on clinical success, eligibility for research incentives, and reliance on third-party manufacturing.
60 Degrees Pharmaceuticals outlined its statistical analysis plan for an interim look at its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis. An interim analysis is planned for the earlier of October 30, 2026 or after 24 of 33 planned patients have been randomized and followed for at least 50 days.
The plan uses conditional power analyses for time to sustained clinical resolution and time to molecular cure, with potential early reporting or sample size increase up to 66 patients. As of this notice, 23 patients had been enrolled. If results support an sNDA, the company aims to pursue a Commissioner’s National Priority Review Voucher before the end of the first quarter of 2028.
60 Degrees Pharmaceuticals is asking stockholders to approve several major governance items at its 2026 virtual annual meeting on August 5, 2026. Holders of 2,659,288 shares outstanding as of July 2, 2026 can vote by telephone or mail.
Stockholders will vote on electing five directors, including proposed new director and audit chair Eric Francois, expanding the 2022 Equity Incentive Plan by 800,000 shares to a total reserve of 962,889 shares, and authorizing a reverse stock split at a ratio between 1:5 and 1:10 at the Board’s discretion. Other proposals include ratifying RBSM LLP as auditor, approving a management success fee tied to a change of control or strategic transaction, and allowing adjournment to solicit additional proxies.
60 DEGREES PHARMACEUTICALS, INC. President and CEO Geoffrey S. Dow reported an open-market purchase of Common Stock. On June 12, 2026, he bought 7,350 shares at an average price of $1.3784 per share. After this transaction, he directly owns 24,131 shares of the company’s Common Stock.
60 Degrees Pharmaceuticals, Inc. states that it intends to apply for a Commissioner’s National Priority Review Voucher if data from its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis support submitting a New Drug Application to the U.S. Food and Drug Administration before the end of the first quarter of 2028.
The company explains that this plan reflects its current development and regulatory strategy and emphasizes that expectations about the trial, any future NDA filing, and any voucher application are forward-looking and subject to risks, including clinical outcomes, regulatory interactions, and broader market and risk factors described in its Form 10-K and Form 10-Q filings.
60 Degrees Pharmaceuticals, Inc. director Francois Eric filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing does not list any stock purchases, sales, option exercises, or other transactions, and serves mainly to register his status as a reporting person.
60 Degrees Pharmaceuticals, Inc. reported that its Board of Directors appointed Eric Francois as a director, effective May 13, 2026. He is a veteran healthcare and life sciences financial executive with over 20 years of experience in investment banking, corporate finance, and board roles.
Francois has held senior positions at Raymond James and Credit Suisse, leading equity, debt, and M&A transactions for biotechnology companies. He also previously served as Chief Financial Officer of SCYNEXIS, Inc., where he raised over $300 million in capital and supported the company through FDA approval and commercial launch. He has prior public company board and committee experience and will receive standard non-employee director compensation, with no special arrangements, family relationships, or related-party transactions disclosed.
Knight Therapeutics Inc. filed Amendment No. 3 to its Schedule 13G/A as an exit filing for 60 Degrees Pharmaceuticals, Inc. The amendment states that as of March 31, 2026 the reporting person no longer beneficially owns any shares of the issuer's common stock (CUSIP 83006G104).
The filing reports 0 shares beneficially owned and a 0% ownership percentage, and is signed on May 15, 2026 by Samira Sakhia on behalf of Knight Therapeutics Inc.